• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Jim Cramer Interviews Cara Therapeutics' CEO on Mad Money

May 24, 2017

 

For those of you who are not familiar with Cara Therapeutics (NASDAQ:CARA), it is a self-described "clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors."

 

Given the opioid epidemic here in the United States, it's no wonder there's a company out there trying to treat pain with new technologies. As Jim Cramer says on Mad Money, "in many cases the cure can be worse than the disease." 

 

If the biotech industry could treat pain with a less addictive drug, then patients will be better off. 

 

Cara is currently working to develop a new class of drug candidates, led by CR845. CR845 targets the body's peripheral nervous system and has demonstrated efficacy in patients with moderate-to-severe pain in its Phase 2 trials. As Dr. Chalmers says, "we think this is a drug that can work across pain types."

 

As mentioned above, in addition to treating moderate to sever pain, the company is developing a drug to help the under-served market of patients afflicted with pruritus. Pruritus is defined as "an unpleasant sensation that provokes the desire to scratch," according to Medscape.

 

The company just recently raised money at its 52-week high, which was a great move to solidify the balance sheet of the company moving forward. These aforementioned drug trails are expensive. It takes years and years, and millions upon millions of dollars to bring a new drug to market.

 

As Cara's CEO Dr. Derek Chalmers mentions in his interview with Cramer, the company has raised now enough money to at least cover two of the indications for the drug. The funding covers the indication for uremic pruritus (chronic kidney disease) all the way through the new drug application. In addition, Cara will have the funding to take their drug's indication for acute post-surgical pain to market, which is currently in Phase 3 trials. 

 

Learn more about Cara Therapeutics in the full video interview with the company's CEO, Dr. Derek Chalmers. 

 

 

Conclusion

 

To learn more about Cara Therapeutics, check out the company's marijuana stock profile in our marijuana stock database. Be sure to subscribe to one or more of our free newsletters so you never miss an important cannabis update. Also, don't forget to connect with The Daily Marijuana Observer on Facebook, Twitter, and Instagram

 

D/M/O

 

Read more articles tagged:

Please reload

LATEST NEWS
Please reload

Please reload

DMO

© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.